Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study.

MLA

Gebhardt, Christoffer, et al. “Potential Therapeutic Effect of Low-Dose Paclitaxel in Melanoma Patients Resistant to Immune Checkpoint Blockade: A Pilot Study.” Cellular Immunology, vol. 360, Feb. 2021, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.cellimm.2020.104274.

APA

Gebhardt, C., Simon, S. C. S., Weber, R., Gries, M., Mun, D. H., Reinhard, R., Holland-Letz, T., Umansky, V., & Utikal, J. (2021). Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study. Cellular Immunology, 360, N.PAG. https://doi.org/10.1016/j.cellimm.2020.104274

Chicago

Gebhardt, Christoffer, Sonja C.S. Simon, Rebekka Weber, Mirko Gries, Dong Hun Mun, Raphael Reinhard, Tim Holland-Letz, Viktor Umansky, and Jochen Utikal. 2021. “Potential Therapeutic Effect of Low-Dose Paclitaxel in Melanoma Patients Resistant to Immune Checkpoint Blockade: A Pilot Study.” Cellular Immunology 360 (February): N.PAG. doi:10.1016/j.cellimm.2020.104274.